Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima

Loading news article.

Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima | WAPE

Bridgebio Presents New Exploratory Cardiac Data From 12-Month Interim Analysis Of FORTIFY, Phase 3 Clinical Trial Of Oral BBP-418 In Individuals With Limb-Girdle Muscular Dystrophy Type 2I/R9, At 31st Annual Congress Of The World Muscle Society In Hiroshima

Article summary

Related companies

Comments —